MGC Pharmaceuticals (ASX:MXC) has achieved positive safety and efficacy results from a safety and toxicology mouse study for a natural supplement formulation.

The pre-clinical study was performed in the Science in Action Laboratory in Ness Ziona, Israel.

The in vivo study was deemed successful with no adverse results recorded from the full panel of hematology and chemistry blood tests.

MGC Pharma expects histology test results analysing the impact of the supplement on major organs from this same study within the next seven days.

“We are very pleased with the positive results achieved in the safety study. Importantly, this study provides further support for the parameters of our phase-two clinical trial in COVID-19 patients currently underway,” Roby Zomer, co-founder and managing director of MGC Pharma, said.

“We look forward to the histology results in the coming week from this important in vivo study, and then the first interim results from our phase two clinical trial in Israel on COVID-19 infected patients that are expected by early August.”

The pre-clinical study was completed on nine mice in three study groups, with three mice per group. The mice in each group were given either 25ul, 50ul or none — the control group — and the mice were observed and tested for clinical changes over seven days.


COVID-19 phase-two study

MGC’s phase-two clinical trial started in Israel at the Nazareth Hospital EMMS and Hillel Yaffe Hospital in May 2020 and is progressing on schedule.

The significant spike in COVID-19 infection rates in Israel over the past six weeks has led to an increase in patient recruitment applications and the COVID-19 infected patient pool.

The phase-two clinical trial at the Mahatma Gandhi Mission’s Medical College & Hospital in India is also moving forward, with the first patient expected to commence treatment in the coming two weeks.

The significant infection rate increase in India during June and July created strong support from the government for the fast tracking of the trial.